The application discloses methods of treating and/or preventing acute respiratory disorder in a subject in need thereof. The application also discloses a method of treating a viral infection, such as Coronaviridae infection by administering to a subject infected with a virus from Coronaviridae with an agonist or antagonist of CD32. Antibodies and antibody binding fragments thereof are disclosed as treatments, and, in some embodiments, the antibody treatment is an antibody against an epitope in CD32b.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Disclosed herein are engineered guide RNAs, constructs for forming engineered guide RNAs, pharmaceutical compositions thereof, methods of making the engineered guide RNAs, and methods of treating or preventing a diseases and disorders of a subject by administering one or more of the engineered guide RNAs or the constructs for forming the engineered guide RNAs.
The present invention proves mitochondria-targeting nanofibers that are formed by assembly of small-molecule building blocks of amphiphilicity to improve photodynamic cancer therapy. Monomers derived from a pheophorbide a and quinolinium conjugates are described, as well as the formation of nanoparticles, formulations of the compounds, and methods of treatment.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention relates to a catheter that minimizes or eliminates the recirculation of oxygenated blood. The catheter of the present invention can be used to drain blood from multiple points in the patient, namely the superior vena cava, right atrium, and the right ventricle, while returning blood to the patient's pulmonary artery. Further, the catheter of the present invention is less likely to be moved or dislodged than catheters currently available in the art, thus making the catheter particularly useful for portable lung assist devices. The present invention also relates to methods for inserting the catheter into the patient and using the catheter with a lung assist device.
A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
A61M 60/113 - Extracorporeal pumps, i.e. the blood being pumped outside the patient’s body incorporated within extracorporeal blood circuits or systems in other functional devices, e.g. dialysers or heart-lung machines
Virginia Polytechnic Institute and State University (USA)
Inventor
Tamayo-Murillo, Dorathy
Sirlin, Claude
Andre, Michael
Han, Aiguo
Abstract
A method for quantitatively assessing fat of a liver is disclosed. The method comprises: obtaining measured ultrasound data comprising an ultrasound image of the liver and corresponding radio frequency (RF) data of the liver; identifying a field of interest (FOI) in the ultrasound image; determining, for each of a plurality of graphical elements that are within the FOI, values of one or more parameters of interest that are indirect measures of the fat in the liver using the RF data and a pre-defined relationship; and enabling assessment of the fat in the liver based on the determined values.
A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
6.
Gene editing to provide insect resistance in crops
Methods and compositions to produce insect resistance in plants deploy an engineered glutamate receptor-like protein (GLR3.3) that functions in transmitting wound-induced signals from local to systemic plant organs to trigger synthesis of jasmonic acid, a defense hormone.
Methods, systems, and kits for generating placenta-like organoids in suspension or placenta-on-a-chip systems are described herein, as well as methods of use thereof. A placental organoid composition has a plurality of trophoblast cells derived from naïve-like stem cells in suspension cultures. The placental organoid composition can be prepared by seeding a single-cell suspension onto a culture surface in a first medium, centrifuging and incubating the single-cell suspension to form aggregates. A portion of the first media is replaced with a differentiation media and the aggregates are incubated for a period of time during which the aggregates differentiate into placental organoids. The composition can be used to assess drug toxicity and drug screening.
A multimodal optical imaging platform is used to obtain cerebral perfusion-metabolism mismatch metrics for rapid assessment of acute brain injury, ongoing (real-time) feedback to optimize cardiopulmonary resuscitation to improve neurological outcome, and rapid prognosis of recovery. Light of several wavelengths and types is delivered to the tissue, which is then absorbed and scattered by tissue components such as blood and cellular components. Some of this light scatters back to the surface, where it is captured by a detector. The resulting data are processed to obtain blood flow and oxygenation parameters, as well as tissue scattering. These parameters are then combined to calculate metabolism and flow-metabolism coupling/decoupling metrics, which are used to determine ischemic damage, ongoing need for optimal blood flow and oxygenation, and to predict cerebral recovery in patients with acute brain injury during and immediately after cardiac arrest, stroke, traumatic brain injury, etc.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
Disclosed are devices and methods that pertain to a high-throughput formation of flat hydrogels using a hydrogel stamping technique for simultaneously producing a plurality of hydrogels in a multi-well plate. In an embodiment of the disclosed technology, a hydrogel stamp device may include a base; a plurality of rods arranged on the base and configured to be inserted into a plurality of wells of a multi-well plate to enable formation of hydrogels inside the plurality of wells, wherein each of the plurality of rods extends vertically from the base and includes: a base end connected to the base; a hydrophobic end positioned opposite the base end; and a body portion between the base end and the hydrophobic end; and a spacer that surrounds at least part of the base ends of the plurality of rods.
A composition MxABO4 can include: a composition ABO4, wherein M is selected from the group consisting of: Ca, Mg, and Na, wherein M is intercalated with ABO4, wherein x is greater than or equal to 0, wherein A includes at least one selected from the group consisting of: Dy, Er, Sm, Nd, Tm, Pr, Gd, Sc, Y, Eu, Ho, Tb, Bi, Lu, La, Yb, Ce, Zr, Hf, Th, U, Ce, In, Tl, Pa, Pu, Ba, Pb, and Sr, wherein B includes at least one selected from the group consisting of: B, P, V, Cr, As, Si, Ge, N, Nb, Mo, Ru, Sb, W, Re, Bi, Mn, Fe, Se, Tc, Sn, and Co, and wherein the composition ABO4 has a tetragonal structure.
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventor
Ho, Chih-Ming
Khong, Jeffrey
Lee, Megan
Zarrinpar, Ali
Kim, Viki Eunbi
Warren, Curtis
Abstract
The present disclosure includes systems and methods for calculating a dosage of one or more medications. Some aspects include determining a dosage for a patient after an organ transplant, at least by determining a first dosage of a drug given to a patient on a first day, determining a first serum level of the patient associated with the first day, calculating a second dosage of the drug based on a first ratio between the first dosage and the first serum level, and generating a first output based on the second dosage. Some aspects include determining a fourth dosage of the drug based on: a second ratio between the second dosage and a second serum level and a third ratio between a third dosage and a third serum level. Some aspects include generating a second output based on the fourth dosage, the fourth dosage associated with a fourth time period.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
12.
IMMUNE CELL INHIBITION BY IMMUNE CHECKPOINT ENGAGERS
The invention provides cells that have an increased immune checkpoint engagement function (Immune Checkpoint Engager “ICE” cells). The ICE cells comprise an engager molecule' expressed on a cell surface, wherein said engager molecule engages with an immune checkpoint molecule on an immune cell, wherein said engager molecule is expressed at least at a level that protects said ICE cell from being killed by said immune cell.
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
13.
IMPROVED SOLID-STATE IONIC CONDUCTING MATERIALS AND METHODS OF MAKING THE SAME
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Ban, Chunmei
Zhang, Wei
Harris, Stephen J.
Abstract
Improved solid electrolyte materials and methods of treating solid electrolyte materials to yield improved solid electrolyte material are described. The improved solid electrolyte material includes one or more near surface regions to which compressive stress is applied via ion implantation in order to strengthen the solid electrolyte material against, e.g., anode material dendrite penetration. Methods of treating the solid electrolyte material include subjecting the solid electrolyte material to ion implantation to thereby create a first and second region having ions implanted therein. The ion fluence in the second region may be greater than the ion fluence in the first region.
222S compound, carbon particles, and halogenated lithium phosphorous sulfide (LPS-X) particles containing an LPS-X (X is F, Cl, Br, and/or I) compound are provided. The LPS-X particles have crystallinity which can be confirmed with XRD of the LPS-X particles or the mixture showing XRD peaks indicative of crystalline LPS-X. The mixture does not include lithium phosphorous sulfide (LPS) particles made of an LPS compound. The mixture is ball-milled to provide a ball-milled composite material. At least part of the LPS-X compound contained in at least part of the LPS-X particles is converted to the LPS compound. XRD of the ball-milled composite material shows none of the XRD peaks indicative of crystalline LPS-X.
C01B 25/14 - Sulfur, selenium, or tellurium compounds of phosphorus
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 10/0585 - Construction or manufacture of accumulators having only flat construction elements, i.e. flat positive electrodes, flat negative electrodes and flat separators
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
H01M 4/02 - Electrodes composed of, or comprising, active material
15.
METHOD FOR MANUFACTURING SOLID-STATE BATTERY DEVICE
A method of manufacturing a solid-state battery device is provided. The method comprises: continuously supplying a first composite sheet that includes a cathode layer and a solid electrolyte layer formed on the cathode layer; continuously supplying an aluminum-containing sheet onto the first composite sheet so that the aluminum-containing sheet is positioned on the solid electrolyte layer of the first composite sheet; continuously roll-bonding the aluminum-containing sheet and the first composite sheet in order to provide a second composite sheet that includes the cathode layer; continuously supplying, onto the second composite sheet, a third composite sheet that includes a lithium-containing layer and a conductive layer; and continuously roll-bonding the second composite sheet and the third composite sheet so that the lithium-containing layer and the aluminum-containing layer are compressed to form a prelithiated anode.
H01M 10/0585 - Construction or manufacture of accumulators having only flat construction elements, i.e. flat positive electrodes, flat negative electrodes and flat separators
A solid-state battery device is provided. The present disclosure relates to a solid-state battery comprising a cell including: a positive electrode, a negative electrode, and a solid electrolyte disposed between the positive electrode and the negative electrode. The negative electrode includes first particles containing silicon and second particles containing a material configured to form an alloy with lithium. The second particles are softer than the first particles and are configured to compensate for changes in size of the first particles during charge and discharge cycles of the solid-state battery, so that when the first particles expand in size, the size of the second particles is compressed at a given pressure applied to the solid-state battery, and when the first particles shrink in size, the size of the second particles is expanded at a given pressure applied to the solid-state battery.
H01M 10/0585 - Construction or manufacture of accumulators having only flat construction elements, i.e. flat positive electrodes, flat negative electrodes and flat separators
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
Described herein are biodegradable compositions and methods of using thereof. Such biodegradable compositions exhibit controllable or modifiable degradation rates by the inclusion of one or more additives therein. Such biodegradable compositions can be used to form articles and products which can be degraded by microbes, such as in marine environments.
xx) and silicon carbide (SiC) protection layers on the SiMPs to alleviate severe volume change, and removing the n-hexane by evaporation through thermal treatment to obtain the SiMP/LSG composite anode material. This method significantly improves the cycling performance of SiMPs, effectively doubling the cycle life of batteries compared with simple physical mixing methods, thus providing a scalable and efficient solution to produce high-performing SiMP composite anode materials in lithium-ion batteries.
Understanding the function of rare non-coding variants represents a significant challenge. Using MapUTR, a screening method, we studied the function of rare 3' UTR variants affecting mRNA abundance post-transcriptionally. Functional MapUTR variants were enriched in microRNA- or protein-binding sites and may underlie outlier gene expression in tumors. Further, we introduce untranslated tumor mutational burden (uTMB), a metric reflecting the amount of somatic functional MapUTR variants of a tumor and show its potential in predicting patient survival. Through prime editing, we characterized three variants in cancer-relevant genes (MFN2, FOSL2, and IRAK1), demonstrating their cancer-driving potential. Our disclosure elucidates the function of tens of thousands of non-coding variants, nominates non-coding cancer driver mutations, and demonstrates methods for their use in the management of cancers.
20.
METHODS FOR PREDICTING DISEASE ONSET RISK AND SYSTEMS FOR SAME
Provided are methods of training a model to predict a disease onset risk. Aspects of the methods include obtaining a plurality of electronic health records, dividing the subjects into a first set for machine learning model training and a second set for machine learning evaluation, training a machine learning model using the electronic health records of the first set of subjects, evaluating the machine learning model using the electronic health records of the second set of subjects and identifying from the trained and evaluated machine learning model one or more features of the subjects that predict the disease onset risk. In some embodiments, the one or more features are one or more sex-specific features. Also provided are methods of predicting a disease onset risk in a subject, methods of clinically evaluating the presence of a disease in a subject and methods of treating a subject predicted to be at risk of developing a disease. Embodiments of the invention are computer-implemented methods. Systems and non-transitory computer-readable mediums for performing the subject methods are also provided.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
21.
METHODS OF REDUCING FOREIGN BODY RESPONSE AND ENCRUSTATION OF DEVICES
Disclosed herein are methods of reducing the foreign body response of implanted medical devices. Also disclosed herein are methods of reducing encrustation of implanted medical devices such as long term use catheters.
A base station information-based vendor classification process includes extracting, decoding, and grouping the base station information. The grouped base station information is a list associated with types of cellular network technology that is filtered based on the types used by the transmitters. The filtered list is converted to vectors of feature/value pairs, encoded, and provided to a pre-trained classifier. The classifier provides a classification confidence for base station vendors, and an action can be taken based on a comparison between the classification confidence and a list of allowed vendors.
Methods and systems to validated physiologic waveform reliability and uses thereof are provided. A number of embodiments describe methods to validate waveform reliability, including blood pressure waveforms, electrocardiogram waveforms, and/or any other physiological measurement producing a continuous waveform. Certain embodiments output reliability measurements to closed loop systems that can control infusion rates of cardioactive drugs or other fluids in order to regulate blood pressure, cardiac rate, cardiac contractility, and/or vasomotor tone. Further embodiments allow for waveform evaluators to validate waveform reliability based on at least one waveform feature using data collected from clinical monitors using machine learning algorithms.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Most drugs entering clinical trials fail, often related to an incomplete understanding of the mechanisms governing drug response. Machine learning techniques hold immense promise for better drug response predictions, but most have not reached clinical practice due to their lack of interpretability and their focus on monotherapies. Systems and methods described herein relate to DrugCell, an interpretable deep learning model of human cancer cells trained on the responses of 1,235 tumor cell lines to 684 drugs. Tumor genotypes induce states on cellular subsystems which are integrated with drug structure to predict response to therapy and, simultaneously, learn biological mechanisms underlying the drug response. DrugCell predictions are accurate in cell lines and also stratify clinical outcomes. Analysis of DrugCell mechanisms leads directly to design of synergistic drug combinations, which can be validate systematically. DrugCell provides a blueprint for constructing interpretable models for predictive medicine.
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Disclosed herein are methods and systems for engineering glycosylation. The methods and systems may use structure of sequence information of biomolecules to predict glycosylation features. The methods and systems may employ one or more trained algorithms described herein.
A system and method to precipitate calcium hydroxide at low temperatures (T < 40 °C) using an electrolytic reactor with hydrodynamic separation. The calcium can be supplied by any calcium bearing material such as calcium carbonate or basalt rock, or from industrial wastes such as brine or steel slag. The solid feedstock undergoes dissolution, whereas the brine may be utilized as is. Once in solution, the feed stream is directed towards an electrolyzer reactor which comprises a cathode, an anode, and a membrane separator. At the cathode, or in a separate precipitation chamber, an alkaline catholyte solution containing calcium hydroxide (portlandite) and magnesium hydroxide (brucite) precipitates, and hydrogen gas is produced.
Disclosed herein are adeno-associated virus (AAV) vectors comprising capsid protein variants, for example that have tropism for human T-cells. Also disclosed herein are pharmaceutical compositions comprising these AAV vectors and capsid protein variants as well as methods of making such vectors and capsid protein variants. Disclosed herein are methods of using the disclosed AAV vectors and disclosed capsid protein variants.
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (USA)
UNIVERSITY OF MARYLAND, COLLEGE PARK (USA)
UNIVERSITY OF VIRGINIA PATENT FOUNDATION (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
UNIVERSITY OF SOUTH CAROLINA (USA)
Inventor
Hobart, Karl D.
Anderson, Travis J.
Tadjer, Marko J.
Jacobs, Alan G.
Graham, Samuel
Aller, Henry
Hopkins, Patrick
Goorsky, Mark
Khan, Asif
Feygelson, Tatyana I.
Pate, Bradford B.
Abstract
In one aspect, the disclosure relates to a device comprising a plurality of semiconductor layers; a phonon bridge layer formed on the plurality of semiconductor layers; a gate electrode set into the phonon bridge layer and in contact with a surface of the plurality of semiconductor layers; and a diamond layer formed over the phonon bridge layer. The phonon bridge layer can include materials that have a speed of sound in-between the speed of sound for the diamond layer and the speed of sound of the semiconductor layer that is in contact with the phonon bridge layer. In one aspect, the device is a transistor, such as a high electron mobility transistor. The disclosure, in another aspect, relates to methods of making the devices as disclosed herein.
H01L 21/28 - Manufacture of electrodes on semiconductor bodies using processes or apparatus not provided for in groups
H10D 62/83 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials being Group IV materials, e.g. B-doped Si or undoped Ge
H01L 21/768 - Applying interconnections to be used for carrying current between separate components within a device
H01L 23/373 - Cooling facilitated by selection of materials for the device
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventor
Ngo, Wayne
Doudna, Jennifer A.
Satpathy, Ansuman
Stickels, Robert R.
Abstract
The present disclosure provides enveloped delivery vehicles (EDVs) that include a nucleic acid-binding effector polypeptide, and provided a collection of nucleic acids encoding a subject EDV. In some cases, the EDV is streamlined, e.g., lacks certain proteins and/or includes truncated versions of proteins. The present disclosure provides methods of using and producing an EDV of the present disclosure, e.g., for delivery of a nucleic acid-binding effector polypeptide to a eukaryotic cell.
Compositions and methods of treatment for vaginal morbidities are disclosed herein. Methods for the manufacture of vaginal extracellular matrix hydrogel compositions are disclosed.
A system comprises an airflow pathway; a nozzle configured to inject the liquid into the airflow pathway; and a pintle disposed within the nozzle such that an end of the pintle contacts the liquid injected into the airflow pathway, wherein the pintle is configured to impart vibratory energy unto the liquid injected into the airflow pathway.
B05B 17/06 - Apparatus for spraying or atomising liquids or other fluent materials, not covered by any other group of this subclass operating with special methods using ultrasonic vibrations
F02M 27/08 - Apparatus for treating combustion-air, fuel, or fuel-air mixture, by catalysts, electric means, magnetism, rays, sonic waves, or the like by sonic or ultrasonic waves
F02M 61/16 - Details not provided for in, or of interest apart from, the apparatus of groups
Disclosed herein are methods and compositions for the in vivo modification of cell genomes involving delivery of different components of gene editing components from different vectors. The methods and compositions target a heterologous polynucleotide to a target cell-specific locus for insertion into the genome, and for expression of a heterologous polypeptide in place of a native gene. The methods and compositions may be used in the treatment of disease.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
e.g.e.g., chain length, composition, and sequence. In this way, the stochastic properties of the photoresists can be improved. Further, this photoresist platform can also be intrinsically patternable, thereby removing the utilization of PAGs to trigger chemical reactions upon exposure to lithographic radiation.
Disclosed are materials, devices, systems, and methods for an intrinsically conductive adhesive (ICA) that can be used to interconnect solar modules. In some aspects, a method can include acquiring a material comprising an insulating epoxy matrix; synthesizing the ICA by replacing the insulating epoxy matrix with a conducting polymer matrix free of electronic filler material; and optimizing at least one functional property of the ICA by modifying one or more formulations of the ICA including incorporating one or more of a crosslinker, polar dopants, adhesion promoters, or carbon nanotubes into the ICA.
C07C 31/22 - Trihydroxylic alcohols, e.g. glycerol
C07C 317/04 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
C08L 63/00 - Compositions of epoxy resinsCompositions of derivatives of epoxy resins
C09J 163/00 - Adhesives based on epoxy resinsAdhesives based on derivatives of epoxy resins
H01B 1/20 - Conductive material dispersed in non-conductive organic material
H02S 40/34 - Electrical components comprising specially adapted electrical connection means to be structurally associated with the PV module, e.g. junction boxes
35.
SYSTEMS AND METHODS FOR PERFORMING SPEECH DETECTION USING DEPTH IMAGES
Systems and methods for performing speech detection using depth images in accordance with embodiments of the invention are illustrated. One embodiment of the invention includes: a depth sensor; a memory containing a speech detection application; and at least one processor configured by the speech detection application. The speech detection application configures the at least one processor to: capture a sequence of depth images; identify and crop a region of interest from within each depth image, where the cropped region of interest contains a mouth; detect at least one word by providing the sequence of cropped regions of interest to a machine learning model configured to receive a sequence of cropped regions of interest and output at least one detected word from a predetermined vocabulary; and update a user interface of the speech detection system based upon a command corresponding to the detected at least one spoken word.
G10L 15/25 - Speech recognition using non-acoustical features using position of the lips, movement of the lips or face analysis
G10L 25/30 - Speech or voice analysis techniques not restricted to a single one of groups characterised by the analysis technique using neural networks
G10L 25/57 - Speech or voice analysis techniques not restricted to a single one of groups specially adapted for particular use for comparison or discrimination for processing of video signals
Provided is a solid-state battery device. The solid-state battery includes a cell. The cell includes a positive electrode, a negative electrode, and a solid electrolyte layer. The positive electrode includes positive electrode active material particles, solid electrolyte particles, and carbon particles. The positive electrode active material particles include a positive electrode active material configured to bind to lithium ions. The positive electrode active material particles include single crystal particles, each of which does not include polycrystalline grains therein, and thus first and second solid electrolyte materials are absent inside the single crystal particles, but the first solid electrolyte material is in contact with the surface of the single crystal particles. The positive electrode has a lithium ion diffusivity in the range of 1x10-14cm2/s to 1x10-7cm2/s.
H01M 10/0585 - Construction or manufacture of accumulators having only flat construction elements, i.e. flat positive electrodes, flat negative electrodes and flat separators
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
A multiplex network science (MNS) model represents infrastructure of an environment and an installation as a plurality of nodes connected by links, the links defining dependencies between the plurality of nodes. A multiscale system dynamics (MSD) model represents the installation as a plurality of nested subsystems and resource flows connecting the nested subsystems. A hybrid model integrating the MNS model and the MSD model is generated, the hybrid model linking the MNS model and MSD model via boundary conditions representing dependencies between the installation and the infrastructure of the environment. The hybrid model simulates an alteration to the infrastructure of the environment and propagation of effects of the alteration through at least one of the boundary conditions to the installation.
G06F 30/13 - Architectural design, e.g. computer-aided architectural design [CAAD] related to design of buildings, bridges, landscapes, production plants or roads
G06F 111/02 - CAD in a network environment, e.g. collaborative CAD or distributed simulation
A computer-implemented method of analyzing mass spectrometry data is described. The computer-implemented method comprises: acquiring a first data representing a mass spectrometry measurement of an unknown molecule; identifying one or more shifts in spectral peaks in the first data by comparing the first data to a second data representing a mass spectrometry measurement of a known molecule; and deriving structural information of the unknown molecule based on the one or more shifts.
This disclosure provides systems, methods, and apparatus related to lithium phosphorus sulfide halide-polymer composites. In one aspect, a lithium phosphorus sulfur halide (LiPSX) solution and a polymer solution are provided. X is chlorine, bromine, iodine, or combinations thereof. LiPSX of the LiPSX solution and a polymer of the polymer solution are precipitated by mixing the LiPSX solution and the polymer solution. A LiPSX solvent of the LiPSX solution and a polymer solvent of the polymer solution are removed from the LiPSX and the polymer to form polymer-embedded LiPSX.
Catalysts and methods for dinitrogen conversion to secondary silyamines or ammonia (N2RR) are provided. The catalysts are a metalacyclic platform characterized by a pocket with tunable dimensions and conditions. The catalysts show dramatically improved N2RR activity compared to previously reported early d-block catalysts. The tetraphenolate-supported bimetallic lanthanide or group IV metal complex undergoes multiple two-electron reductions, the last of which leads to the reductive activation of dinitrogen. The inclusion of a weak acid and silyl electrophiles during the reduction enables the catalytic conversion of N2 to purely secondary amines.
Intracellular delivery of a genetic construct to immune cells including: obtaining a deterministic mechanoporation (DMP) platform that includes a substrate having a surface and a plurality of capture sites, each said capture site having a boundary shape at the surface adapted and configured to support thereon a cell, and each said capture site having a bottom and including a sub-micron-scale projection extending from the bottom toward the surface of the substrate, wherein said projection is adapted and configured to penetrate a cell membrane and/or wall of the cell, and wherein the substrate has a plurality of aspiration vias situated at the bottom of the capture sites; introducing the cells to the surface in a liquid media; capturing the cells within the capture sites by applying a first hydrodynamic force; applying a second hydrodynamic force on the captured cell and locally rupturing the membrane and/or wall of the cell with the projection, introducing the genetic construct into the cells, and releasing the porated cells from the capture sites. Also disclosed are methods of chimeric antigen receptor (CAR) T cell adoptive immunotherapy and T cell receptor (TCR) therapy.
The J. David Gladstone Institutes, a testamentary trust established under the will of J. David (USA)
The Regents of the University of California (USA)
Inventor
Mcdevitt, Todd C.
Vasic, Ivana
Abstract
Described herein are compositions, systems, and methods for obtaining primordial germ cells (PGCs) from pluripotent stem cells (PSCs). Inhibiting or bypassing tight junction formation in a population of pluripotent stem cells to generate a modified cell population, and contacting the modified cell population with BMP. Where inhibiting or bypassing tight junction formation includes incubating the population of pluripotent stem cells.
A robotic assembly includes a plurality of rigid links formed from a first material and an elastic joint interconnecting a pair of rigid links of the plurality of rigid links. The elastic joint is formed from a second material. The robotic assembly also includes a conductive sensor coupled to the elastic joint and extending along at least one rigid link of the plurality of rigid links. The conductive sensor is formed from a third material. The plurality of rigid links, the elastic joint, and the conductive sensor are formed during a single printing process by a multi-material printer.
The present invention relates to non-toxic, biodegradable adhesive compositions comprising the reaction product of a linear dicarboxylic acid, a saturated triol, and an aromatic amino acid. In certain embodiments, the adhesive compositions comprise the reaction product of sebacic acid terminated-poly(ethylene glycol), glycerin, and L-DOPA. The present invention also relates to methods of using the adhesive compositions for the closure of various wounds. Further, the present invention provides surgical closure devices comprising an adhesive composition.
Disclosed herein, inter alia, are compounds and methods for inhibiting Caspase 6 and the treatment of diseases, pharmaceutical composition including a compound as described herein and a pharmaceutically acceptable excipient and methods of inhibiting human Caspase 6 protein activity, the method including: contacting the human Caspase 6 protein with a compound as described herein.
C07C 311/08 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Solid state battery apparatus are provided. The present disclosure relates to a solid state battery comprising a cell which comprises a cathode, an anode, and a solid electrolyte positioned between the cathode and the anode. The anode comprises first particles comprising silicon and second particles comprising a material configured to form an alloy with lithium. The second particles are substantially softer than the first particles and configured to compensate for size changes of the first particles during charging and discharging cycles of the solid state battery such that, as the first particles expand in size, the second particles are compressed in size at a given pressure applied to the solid state battery and further such that, as the first particles shrink in size, the second particles expand in size at a given pressure applied to the solid state battery.
Methods for making solid state battery apparatus are provided. The method comprises continuously supplying a first composite sheet comprising a cathode layer and a solid electrolyte layer formed on the cathode layer. The method comprises continuously supplying an aluminum-containing sheet over the first composite sheet such that the aluminum-containing sheet is placed on the solid electrolyte layer of the first composite sheet. The method comprises continuously roll-bonding the aluminum-containing sheet and the first composite sheet to provide a second composite sheet comprising the cathode layer. The method comprises continuously supplying, over the second composite sheet, a third composite sheet comprising a lithium-containing layer and a conductive layer. The method comprises continuously roll-bonding the second composite sheet and the third composite sheet such that the lithium-containing layer and the aluminum-containing layer are compressed together to form a prelithiated anode.
H01M 50/403 - Manufacturing processes of separators, membranes or diaphragms
H01M 4/134 - Electrodes based on metals, Si or alloys
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
H01M 10/0587 - Construction or manufacture of accumulators having only wound construction elements, i.e. wound positive electrodes, wound negative electrodes and wound separators
48.
ELECTRODE COMPOSITE MATERIALS, ELECTRODES COMPRISING SAME, AND ALL SOLID STATE BATTERIES COMPRISING SAME, AND METHODS OF MAKING SAME
An electrode composite material and a method of making same are disclosed. A mixture that includes lithium sulfide (Li2S) particles containing a Li2S compound, carbon particles, and halogenated lithium phosphorous sulfide (LPS-X) particles containing an LPS-X (X is F, Cl, Br, and/or I) compound are provided. The LPS-X particles have crystallinity which can be confirmed with XRD of the LPS-X particles or the mixture showing XRD peaks indicative of crystalline LPS-X. The mixture does not include lithium phosphorous sulfide (LPS) particles made of an LPS compound. The mixture is ball-milled to provide a ball-milled composite material. At least part of the LPS-X compound contained in at least part of the LPS-X particles is converted to the LPS compound. XRD of the ball-milled composite material shows none of the XRD peaks indicative of crystalline LPS-X.
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/136 - Electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
An electrode composite material and a method of making same are disclosed. A mixture that includes lithium sulfide (Li2S) particles containing a Li2S compound, carbon particles, and halogenated lithium phosphorous sulfide (LPS-X) particles containing an LPS-X (X is F, Cl, Br, and/or I) compound are provided. The LPS-X particles have crystallinity which can be confirmed with XRD of the LPS-X particles or the mixture showing XRD peaks indicative of crystalline LPS-X. The mixture does not include lithium phosphorous sulfide (LPS) particles made of an LPS compound. The mixture is ball-milled to provide a ball-milled composite material. At least part of the LPS-X compound contained in at least part of the LPS-X particles is converted to the LPS compound. XRD of the ball-milled composite material shows none of the XRD peaks indicative of crystalline LPS-X.
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
B60L 50/64 - Constructional details of batteries specially adapted for electric vehicles
H01M 4/136 - Electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
50.
INJECTABLE SHEAR-THINNING HYDROGEL CONTAINING THERAPEUTIC AGENT FOR ENHANCED TUMOR THERAPY
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Boston Scientific Scimed, Inc. (USA)
Inventor
Kim, Hanjun
Xu, Chun
Jabbarzadeh, Ehsan
Oklu, Rahmi
Khademhosseini, Alireza
Abstract
We have developed novel shear-thinning biomaterials using silica nanoparticles, gelatin-based polymers and small molecules such as doxorubicin. Shear-thinning biomaterial technology offers enables polymers and drugs loaded inside such polymers to be easily delivered directly through catheters into target area for use, for example, in cancer therapy and immunotherapy. When a force above a certain threshold is applied to inject such materials, they “thin” and behaves as a semi-solid, allowing the material to readily flow through a catheter. When the force is removed, the material instantly becomes a soft solid with significant cohesive properties that prevent it from dislodging or breaking up.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
WASHINGTON UNIVERSITY (USA)
Inventor
Sarpong, Richmond
Wright, Brandon
Akiyama, Sota
Nedungadan, Thomas
Majumdar, Susruta
Mclaughlin, Jay P.
Abstract
Morphine derivative comprise a modification of the framework of the molecule, wherein the derivative possesses novel bioactivity profiles that are different from morphine, and can address pain without an associated untoward effect, such as respiratory depression, addiction, etc., or may be used to treat pain without an addictive side effect or respiratory depression, or may be applied as an alternative to naloxone for addressing opioid overdose.
C07C 13/64 - Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with more than three condensed rings with a bridged ring system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
53.
INTEGRATED DEVICE FOR COLLECTION, PROCESSING, STABILIZATION AND STORAGE OF SAMPLES AND METHODS OF USE THEREOF
A device for collection, filtration and stable storage of cell-free DNA, extracellular RNA and protein analytes from a saliva sample, and methods of use thereof, as well as methods of use of guanidine thiocyanate as a stabilization agent for stabilizing nucleic acid species. A saliva testing kit is also described.
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (USA)
Inventor
Choudhary, Hemant
Rodriguez, Alberto
Gladden, John M.
Simmons, Blake A.
Abstract
The present invention provides for a method for increasing saccharification yield comprising: (a) providing a pretreated biomass comprising a pretreatment (PT) solvent, (b) adding or introducing water to the pretreated biomass to form a water-added slurry, and (c) removing or separating the PT solvent from the water-added slurry.
A method comprises acquiring a plurality of multimodal physiological signals, dividing the plurality of multimodal physiological signals into a plurality of sliding windows containing a respective multimodal physiological signal, selecting a subset of the plurality of sliding windows that contain the respective multimodal physiological signal, modifying the respective multimodal physiological signal contained in the subset of the plurality of sliding windows; providing, as one or more inputs to a machine learning model, the plurality of sliding windows that contain the respective multimodal physiological signal and the subset of the plurality of sliding windows that contain the respective modified multimodal physiological signal; and identifying, using one or more outputs of the machine learning model, at least one moment of opioid administration.
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
57.
SOLID-STATE BATTERY AND MANUFACTURING METHOD THEREFOR
The present disclosure provides: an additive material added to a sulfide-containing solid electrolyte material for use in a solid-state battery; a solid-state battery in which the additive material is used in the solid electrolyte material; and a method for manufacturing the solid-state battery. Due to the additive material provided in the present invention, the solid-state battery using the additive material can operate under pressure relatively lower than that of a solid-state battery with no additive material.
H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
H01M 10/0585 - Construction or manufacture of accumulators having only flat construction elements, i.e. flat positive electrodes, flat negative electrodes and flat separators
The present disclosure provides: an additive material to be added to a sulfide-containing solid-state electrolyte material for use in a solid-state battery; a solid-state battery using such an additive material in a solid-state electrolyte material; and a method for manufacturing such a solid battery. Due to the additive material provided in the present application, the solid-state battery using such an additive material can operate under relatively low pressure as compared to a solid-state battery without such an additive material.
H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
H01M 10/0585 - Construction or manufacture of accumulators having only flat construction elements, i.e. flat positive electrodes, flat negative electrodes and flat separators
The disclosure provides methods for coating viruses and viral particles with membrane fragments to circumvent immune responses, the coated viruses and viral particles resulting therefrom, and the use of the coated viruses and viral particles in various applications, including gene therapy and genome engineering applications. The disclosure further provides methods for making ligand-modified viruses and viral particles, the ligand-modified modified viruses and viral particles resulting therefrom, and the use of the ligand-modified modified viruses and viral particles in various applications, including gene therapy and genome engineering applications.
Methods, devices and systems are described for digitally creating new scents or digitally dispensing gas, vapor, or liquid substances. A device includes a container or replaceable cartridge including one or more chambers containing one or more scented substances; a housing structured to include a compartment to hold the cartridge, an opening to allow the one or more scented or unscented substances to dispense to an outer environment from the device, and one or more transporting channels formed between the compartment and the opening, in which each of the one or more transporting channels is configured to deliver a scented substance from the corresponding chamber to the opening for delivering a scent from the one or more scented substances; and an actuator switch arranged in a corresponding transporting channel and rapidly operable to move between an open position and closed position based on an applied signal to selectively allow passage of the scented or unscented substance from the corresponding transporting path.
Techniques for measuring cell dynamics include training a segmenting model with segmenting training data that indicates cell boundaries for each of one or more images. A tracking model is trained with linkages between a boundary of each cell in a first image and in a second image in the segmenting training data. Observations that indicate multiple images of a microscopic video are retrieved. Boundary data that indicates a boundary of each cell in at least two images of the observations is generated based on the observation data and the segmenting model. Tracking data that indicates a linkage between a boundary of a first cell in a first image and in a second image is generated based on the boundary data and the tracking model. Cell dynamics of the first cell are generated based on the boundary of the first cell in the first and second images and sent.
A system and method to precipitate calcium hydroxide at low temperatures (T<40° C.) using an electrolytic reactor with hydrodynamic separation. The calcium can be supplied by any calcium bearing material such as calcium carbonate or basalt rock, or from industrial wastes such as brine or steel slag. The solid feedstock undergoes dissolution, whereas the brine may be utilized as is. Once in solution, the feed stream is directed towards an electrolyzer reactor which comprises a cathode, an anode, and a membrane separator. At the cathode, or in a separate precipitation chamber, an alkaline catholyte solution containing calcium hydroxide (portlandite) and magnesium hydroxide (brucite) precipitates, and hydrogen gas is produced.
C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
C25B 15/04 - Regulation of the inter-electrode distance
C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes
63.
COMPOSITIONS AND METHODS OF MODULATING RNA AND PROTEIN INTERACTIONS
Provided are compositions and methods of treating Coronavirus disease 2019 (COVID-19) in a subject, the method including administering to the subject a therapeutically effective amount of a composition comprising an exogenous nucleic acid and delivering the exogenous nucleic acid into a cell, wherein the exogenous nucleic acid comprises an antisense oligonucleotide, a small interfering RNA (siRNA), or locked nucleic acid, and wherein the exogenous nucleic acid binds to a target RNA and modulates gene expression of the target RNA, thereby treating Coronavirus disease 2019 (COVID-19) in the subject.
The present disclosure provides conjugates and systems for modulating the activity of a ligand-binding polypeptide such as a D2 dopamine receptor. Such conjugates comprising an affinity agent, a linker; a photoisomerizable group and a ligand that binds to a target ligand-binding polypeptide. The present disclosure provides methods of modulating the activity of a D2 dopamine receptor. The present disclosure provides methods of treating Parkinson's disease in an individual.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
The present disclosure provides additive materials to be added to sulfide-containing solid electrolyte materials for use in solid state batteries, solid state batteries using such additive materials in their solid electrolyte materials, and methods of making such solid state batteries. The additive materials provided herein allow the solid state batteries using such additive materials to operate under relatively lower pressures compared to solid state batteries without such additive materials.
The present disclosure provides additive materials to be added to sulfide-containing solid electrolyte materials for use in solid state batteries, solid state batteries using such additive materials in their solid electrolyte materials, and methods of making such solid state batteries. The additive materials provided herein allow the solid state batteries using such additive materials to operate under relatively lower pressures compared to solid state batteries without such additive materials.
Solid state battery apparatus. The solid state battery comprises a cell. The cell comprises a cathode, an anode electrode, and a solid electrolyte layer. The cathode electrode comprises cathode active material particles, solid electrolyte particles and carbon particles. The cathode active material particles comprise a cathode active material configured to bind with lithium ions. The cathode active material particles comprise single crystalline particles, each of which does not include polycrystalline grains therein, such that inside of the single crystalline particles is substantially free of the first and second solid electrolyte material while the first solid electrolyte material contacts surfaces of the single crystalline particles. The cathode electrode has lithium ion diffusibility ranging from about 1×10−14 cm2/s to about 1×10−7 cm2/s.
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
69.
SOLID STATE BATTERIES AND METHODS OF DESIGNING AND MAKING THEREOF
The present disclosure provides methods of designing and making all-solid-state batteries. A set of input data is provided to produce a simulation box containing electrode active material particles and solid electrolyte particles in randomly selected discretized spaces. A compressed simulation box is then generated, such that each of the particles touches at least one neighboring particle. The compressed simulation box data is processed to obtain a relative tortuosity of the SE particles. The steps are repeated to prepare a database comprising sets of input parameters and corresponding relative tortuosities. A desired set of input parameters is selected from the database, and an all-solid-state lithium battery is prepared accordingly.
A method of detecting and/or quantifying the concentration of one or more analytes in a sample uses a vertical flow assay cartridge that includes one or more cartridges having a sample inlet and a sensing membrane populated with a plurality of spots containing one or more types of capture agent(s). A mixture of the sample and detection reagents is loaded into the sample inlet along with signal amplification reagents. The sensing membrane is imaged with a reader device to illuminate and obtain a plurality of time-lapsed images of the sensing membrane containing time-lapsed intensity signals for the spots. The time-lapsed intensity images and/or signals for the spots are processed with machine learning or one or more trained neural networks configured to generate one or more outputs that include a classification of the sample and/or a quantification the amount or concentration of the one or more analytes in the sample.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
73.
LITHIUM PHOSPHORUS SULFUR HALIDE/POLYMER COMPOSITE ELECTROLYTES AND METHODS OF MAKING THEREOF
A process for producing hydrogen from hydrocarbons includes contacting a hydrocarbon with a catalyst and inert particles in a reactor, producing solid carbon and hydrogen based on the contacting, removing a portion of the inert particles from the reactor, heating the portion of the inert particles in a heating loop to produce heated inert particles, returning the heated inert particles to an upper portion of the reactor, and heating the reactor during the contacting based on returning the heated inert particles.
C01B 3/28 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of gaseous or liquid organic compounds of hydrocarbons using moving solid particles
C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,
C10B 49/20 - Destructive distillation of solid carbonaceous materials by direct heating with heat-carrying agents including the partial combustion of the solid material to be treated with moving solid heat-carriers in divided form in dispersed form
C10G 11/02 - Catalytic cracking, in the absence of hydrogen, of hydrocarbon oils characterised by the catalyst used
B01J 8/22 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with fluidised particles with liquid as a fluidising medium gas being introduced into the liquid
Aspects of the present disclosure relate to a device for use in delivering a drug within a subject to a specific cell, tissue, or organ. In some embodiments, the device comprises a metal substrate and polymer composite. In some embodiments, the device has mucoadhesive or bioadhesive properties that bind to epithelial cells inside an artery. Some aspects of the present disclosure also relate to a method of delivering a drug to a target or an organ, such as through usage of the device as disclosed herein.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present disclosure provides methods of designing and making all-solid-state batteries. A set of input data is provided to produce a simulation box containing electrode active material particles and solid electrolyte particles in randomly selected discretized spaces. A compressed simulation box is then generated, such that each of the particles touches at least one neighboring particle. The compressed simulation box data is processed to obtain a relative tortuosity of the SE particles. The steps are repeated to prepare a database comprising sets of input parameters and corresponding relative tortuosities. A desired set of input parameters is selected from the database, and an all-solid-state lithium battery is prepared accordingly.
G16C 60/00 - Computational materials science, i.e. ICT specially adapted for investigating the physical or chemical properties of materials or phenomena associated with their design, synthesis, processing, characterisation or utilisation
G16C 20/70 - Machine learning, data mining or chemometrics
Described herein are devices, systems, and methods used to assess an organ or organ system and determine a course of treatment for said organ, organ system, and/or patient.
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes
A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
A61M 60/139 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel inside a blood vessel, e.g. using grafting inside the aorta, e.g. intra-aortic balloon pumps
A61M 60/148 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel in line with a blood vessel using resection or like techniques, e.g. permanent endovascular heart assist devices
A61M 60/178 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart drawing blood from a ventricle and returning the blood to the arterial system via a cannula external to the ventricle, e.g. left or right ventricular assist devices
A61M 60/216 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller
A61M 60/295 - Balloon pumps for circulatory assistance
A61M 60/515 - Regulation using real-time patient data
A61M 60/531 - Regulation using real-time patient data using blood pressure data, e.g. from blood pressure sensors
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
78.
LONG-CYCLE-LIFE, HIGH-CAPACITY SILICON ANODES AND METHODS OF MAKING AND USING THE SAME
Materials, methods, electrodes, and devices related to high-energy-density, long-life Li-ion batteries are provided. The lithium-ion anode material contains a porous core with silicon and optionally carbon nanotubes, and a dense shell made from lithium vanadium oxide having a disordered rocksalt structure. The lithium vanadium oxide functions as a solid-state mediator layer for the anode material and overcomes the well-known problem of significant volume increase when silicon is lithiated. The lithium vanadium oxide possesses mechanical robustness and prevents electrolyte penetration. For these reasons, the anode material forms a highly stable interface with the battery electrolyte. Experimental data is presented and discussed to demonstrate embodiments of the technology. It is shown that the silicon anode material can reversibly deliver a specific capacity higher than 2500 mA·h/g. The anode material exhibits excellent cycling stability and calendar life at room temperature as well as elevated temperature.
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
79.
METHOD OF REGULATING ALTERNATIVE POLYADENYLATION IN RNA
Provided herein are methods of regulating alternative polyadenylation (APA) of a target RNA in a cell, increasing stability of a target RNA in a cell, preventing degradation of a target RNA in a cell, preventing degradation of a target RNA in a cell, modifying localization of a target RNA in a cell, or increasing synthesis of a protein encoded by a target RNA in a cell, by administering to the cell an RNA regulation unit, wherein the RNA regulation unit comprises an RNA binding protein (RBP) and a gene-targeting agent, wherein the RNA binding protein binds proximal to a poly(A) signal and/or site.
A bioelectronic stent sensor system comprises a bioelectronic stent sensor device comprising a first hollow cylindrical lattice, and a second hollow cylindrical lattice attached to a first surface of the first lattice, comprising a biocompatible magnetoelastic micromesh (BMM), and a computing system communicatively connected to the bioelectronic stent sensor device, comprising a processor and a non-transitory computer-readable medium with instructions stored thereon, which when executed by a processor, perform steps comprising receiving readout current signals from the bioelectronic stent sensor device, and calculating a blood flow rate based on the readout current signals by establishing an empirical relationship between the readout current signals and a flow rate value. Related devices and methods are also disclosed.
A method for separation of non-stationary quasi-periodic signals when limited data is available is described. The method utilizes prior knowledge of time-frequency patterns in the signals to mask and in-paint spectrograms. In one implementation this is achieved through an application-inspired deep harmonic neural network coupled with an integrated pattern alignment component. The network's structure embeds the implicit harmonic priors within the time-frequency domain, while the pattern-alignment method transforms the sensed signal, ensuring a strong alignment with the network.
G06F 18/2134 - Feature extraction, e.g. by transforming the feature spaceSummarisationMappings, e.g. subspace methods based on separation criteria, e.g. independent component analysis
Applicant applied machine learning applied to large compendia of transcriptomic data to enable the decomposition of bacterial transcriptomes to identify independently modulated sets of genes, iModulons, that represent specific cellular functions. The identification of iModulons enables accurate identification of genes necessary and sufficient for cross-species transfer of cellular functions.
A method for optimizing a media formulation or substrate for cellular growth, comprising growing a first plurality of cells in a media formulation, on a substrate, or on a substrate in a media formulation; isolating RNA from the plurality of cells; detecting based on the upregulation or downregulation of an iModulon gene cluster comprising a metabolic, trace element, or stress- related iModulon; and iteratively modifying the media formulation or the substrate to downregulate or upregulate the iModulon gene cluster, growing a second population of cells in the modified media formulation or on the modified substrate, isolating RNA from the second plurality of cells, and detecting optimized expression of the iModulon gene cluster.
Compositions, methods of making, and using modified immune cells such as NK cells to treat cancer, viral and microbial infection. The modified CISH−/− NK cells exhibit hypersensitivity to cytokines such as IL-2 and/or IL-15 and maintain expansion and anti-tumor functions.
Systems and methods to estimate cardinality of multi-join queries are disclosed. The method includes determining sign values and bin indices for joined attributes of a particular relation using corresponding sign functions and bin functions initialized for the joined attributes of a particular relation. The method includes combining the determined sign values to obtain a combined determined sign value and combining the determined bin indices to obtain a combined determined bin index for a particular tuple in the particular relation stream. The method includes creating a tuple sketch based on the combined determined sign value and the combined determined bin index. The method includes creating relation sketches for corresponding relations. The relation sketch is created by accumulating, on a relation basis, tuple sketches of corresponding tuples in the particular relation stream. The method includes, combining, at inference, the relation sketches to estimate a cardinality of the multi-join query.
Systems and methods for preprocessing input images in accordance with embodiments of the invention are disclosed. One embodiment includes a method for performing inference based on input data, the method includes receiving a set of real-valued input images and preprocessing the set of real-valued input images by applying a virtual optical dispersion to the set of real-valued input images to produce a set of real-valued output images. The method further includes predicting, using a machine learning model, an output based on the set of real-valued output images, computing a loss based on the predicted output and a true output, and updating the machine learning model based on the loss.
Systems and methods for implementation of a disposable miniaturized implant for treatment of Post-Operative Ileums (POI), a miniaturized implant for treating chronic GI dysmotility (e.g., dysphagia, gastroesophageal reflux disease (GERD), nausea, functional dyspepsia, blockage of transit, and gastroparesis, inflammatory bowel disease) and obesity, by providing electrical stimulation to the part of bowel going through surgery to expedite the healing process while recording the smooth muscle activities simultaneously, or providing stimulation on a treatment location of the GI tract or the branch of the vagus nerve. Systems and methods are also provided for non-invasive, transcutaneous stimulation of anatomy within the abdomen of the patient.
A deep learning-based digital/virtual staining method and system enables the creation of digitally/virtually-stained microscopic images from label or stain-free samples. In one embodiment, the method of generates digitally/virtually-stained microscope images of label-free or unstained samples using fluorescence lifetime (FLIM) image(s) of the sample(s) using a fluorescence microscope. In another embodiment, a digital/virtual autofocusing method is provided that uses machine learning to generate a microscope image with improved focus using a trained, deep neural network. In another embodiment, a trained deep neural network generates digitally/virtually stained microscopic images of a label-free or unstained sample obtained with a microscope having multiple different stains. The multiple stains in the output image or sub-regions thereof are substantially equivalent to the corresponding microscopic images or image sub-regions of the same sample that has been histochemically stained.
Disclosed are sulfated cellulose nanofibrils, methods of making sulfated cellulose nanofibrils, and methods of spinning the sulfated cellulose nanofibrils into high-strength fibers. The sulfated cellulose nanofibrils may be formed using a chlorosulfonic acid treatment.
A device for tissue mechanical property detection during robotic surgery, comprising a sensor frame having proximal and distal ends and a length therebetween, a force sensor disposed along the length of the sensor frame, and a displacement sensor configured to measure a position of the sensor frame. Related systems and methods are also disclosed.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
92.
RAPID PROCESS FOR VAPOR-DEPOSITED ZIF-8 METAL ORGANIC FRAMEWORK (MOF) FOR LOW-K DIELECTRIC SEAMLESS HIGH ASPECT RATIO GAP FILL
A process for forming a vapor-deposited ZIF-8 metal organic framework includes: conducting a gas surface reaction between an ALD-deposited ZnO and 2-methylimidazole to form a vapor-deposited ZIF-8 metal organic framework, wherein the gas surface reaction is conducted at a temperature greater than 140 C, and wherein the gas surface reaction is conducted at a pressure of less than 1000 mTorr. In a particular embodiment, the gas surface reaction is conducted at a temperature of 160 C. A process for preparing a laminate includes: performing ALD of zinc oxide as a base between 1 nm to 10 nm in thickness, exposing 2-methylimidazole vapor phase linker at chemical vapor deposition at a temperature range of greater than 140 C to less than or equal to 180 C in a vacuum condition, and cycling of the ZnO ALD and 2-methylimidazole exposure to deposit a film or fill a gap.
C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
H01L 21/768 - Applying interconnections to be used for carrying current between separate components within a device
93.
SURGICAL REMOVAL OF HEMORRHAGED BLOOD FROM INSIDE A PATIENT'S BODY
Provided are methods of removing hemorrhagic blood from a body region of a patient, such as from the brain. The methods can include recording X-ray images of the body region and the blood, thereby allowing for the selection of a desired trajectory from the surface of the body to the blood. A sheath is inserted into the body along this desired trajectory. The sheath can have X-ray visible fluoroscopic markers that help ensure correct three-dimensional orientation of the sheath during insertion. Afterwards, the hemorrhaged blood can be removed through the open, internal lumen of the sheath. Also provided are blood removal devices that can be inserted into the sheath, thereby helping to remove the blood from the patient. Such devices can have a cutting element that cuts the solidified blood, thereby aiding in its removal from the patient.
A61B 90/11 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
A61B 1/015 - Control of fluid supply or evacuation
Provided are bifunctional molecules for targeted deamidation. In some instances, the target for deamidation is amyloid-β (Aβ). For example, in certain embodiments, provided are bifunctional molecules comprising an Aβ targeting moiety stably associated with (1) a deamidation agent or (2) a deamidation agent-binding moiety. According to some embodiments, the target for deamidation is Aβ42 and the Aβ targeting moiety is an Aβ42 targeting moiety. Also provided are compositions and methods for deamidating Aβ in a subject in need thereof, e.g., to reduce or prevent Aβ neurotoxicity in the subject.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
University of Central Florida Research Foundation, Inc. (USA)
The Regents of the University of California (USA)
Inventor
Pourmohammadi Fallah, Yaser
Toghi, Behrad
Valiente Romero, Rodolfo
Pedarsani, Ramtin
Abstract
Described herein relates to a system and method for autonomous vehicle navigation. The technique may combine a Hybrid Predictive Network (HPN) and a Value Function Network (VFN), along with a safety prioritizer, to enhance decision-making and safety. The HPN, built on a symmetric encoder-decoder architecture, may utilize a series of observations to predict future scenarios. The VFN may also estimate state-action value functions, combining HPN's predictive capabilities with decision-making, improving navigation. A multi-step prediction chain may also use the HPN to generate future hypotheses based on observation history. The safety prioritizer, integrated within the VFN, may be configured to penalize high-risk actions, masking them when selected, increasing safety. Additionally, the system may apply deep reinforcement learning for high-level policy creation for safe tactical decision-making. The method may optimize social utility and/or may increase sample efficiency and safety, making significant strides in autonomous vehicle operation.
Provided are methods of contextual decoding and/or speech decoding from the brain of a subject. The methods include decoding neural or optical signals from the cortical region of an individual, extracting context-related features and/or speech-related features from the neural or optical signals, and decoding the context-related features and/or speech-related features from the neural or optical signals. Contextual decoding and speech decoding systems and devices for practicing the subject methods are also provided.
G10L 15/24 - Speech recognition using non-acoustical features
A61F 4/00 - Methods or devices enabling patients or disabled persons to operate an apparatus or a device not forming part of the body
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
G10L 13/02 - Methods for producing synthetic speechSpeech synthesisers
G10L 15/14 - Speech classification or search using statistical models, e.g. Hidden Markov Models [HMM]
G10L 15/22 - Procedures used during a speech recognition process, e.g. man-machine dialog
G10L 25/18 - Speech or voice analysis techniques not restricted to a single one of groups characterised by the type of extracted parameters the extracted parameters being spectral information of each sub-band
G10L 25/24 - Speech or voice analysis techniques not restricted to a single one of groups characterised by the type of extracted parameters the extracted parameters being the cepstrum
G10L 25/63 - Speech or voice analysis techniques not restricted to a single one of groups specially adapted for particular use for comparison or discrimination for estimating an emotional state
97.
MULTIPURPOSE, MULTI-FUNCTIONALIZED LIPID COATED BEADS AND METHODS OF PRODUCTION
Bead constructs of sizes in the nanometer to micrometer range with a primary functionalization of a lipid membrane with embedded anchor peptides are provided. The anchor peptides may be adapted for a secondary functionalization of active molecules that are bound to the anchor peptides by transpeptidation or similar process. The functionalized bead platform can be adaptable and used in many different applications including biochemical and cellular assays, molecular diagnostics such as protein-protein interactions, protein-DNA interactions, DNA detection, separations, purifications, imaging, and microfluidics.
G01N 33/544 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
The present disclosure relates to, among other things, methods for degrading targeted surface proteins using the ubiquitin pathway by using a dual binding agent that binds the targeted surface protein and a membrane-associated ubiquitin E3 ligase. The disclosure also provides compositions and methods useful for producing such dual binding agents, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various diseases such as cancers.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
99.
CAPACITIVE-LOAD DRIVING CIRCUIT BASED ON FLYING BATTERIES
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
Inventor
Pillonnet, Gael
Oukassi, Sami
Mercier, Patrick
Abstract
The invention is a driving device with a network of N driving units, each having an energy-storing element and a switching matrix for series or parallel connection. A State of Charge mapping unit measures the state of charge for N elements, identifying a first set with low charge, and a second set. A control unit commands switching matrices through invest and recovery phases in cycles. In each cycle, a stacking sequence configures the network for capacitive load connection. The control unit calculates the sequence so that, during the recovery phase, elements in the first set receive charges from the capacitive load, previously supplied during the invest phase by elements in the second set.
H02M 3/07 - Conversion of DC power input into DC power output without intermediate conversion into AC by static converters using resistors or capacitors, e.g. potential divider using capacitors charged and discharged alternately by semiconductor devices with control electrode
An example apparatus and method to form an integrated microlens coupler of the present disclosure are disclosed. The apparatus includes a substrate, a waveguide formed on the substrate to propagate a light beam in a horizontal direction, a self-aligned containment ring formed on the substrate, and an optical element formed on the substrate between the waveguide and free space, wherein the self-aligned containment ring defines a boundary and a location of the optical element on the substrate, wherein the optical element is to transform the light beam in the waveguide to a desired optical mode in the free space.
